Az immunrendszer állapota gyermekkori malignus daganatok terápiáját követoen

Translated title of the contribution: The function of the immune system after the treatment of pediactric malignant diseases

Judit Gadó, Barbara Schlick, Olga Bárány, Júlia Németh, J. Müller, Monika Csóka, T. Constantin, Eszter Vonnák, Renáta Böcskei, P. Hauser, Gábor Kovács

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Currently, malignancies in childhood can be cured in 70 percent of the cases. However, the intensive cytostatic therapy may lead to late side effects influencing quality of life. Aim of the study: Analysis of the reconvalescence of the immune functions after completion of therapy for malignancies in children. Patients: 88 long-term survivers (51 boys, 37 girls) were investigated (43 acute lymphoid leukemia, 15 lymphoma, 20 bone tumors, 10 other solid tumors). Mean age at the time of diagnosis was 7.8 years (1 mo-17.7 years). Methods: The following parameters were investigated: serum immunglobulin levels after completion of the chemotherapy and in the next 4 years thereafter, lymphocyte subpopulations in the periferal blood by flow-cytometry and cellular immunity by in vitro tests (natural killer aktivity, antibody-dependent cellular cytotoxicity, mitogen-induced T- and B-cell blastic transformations). Results: Lower serum immunglobulin (IgG) levels could be detected in patients with leukemia after completion of the chemotherapy (8.8 ± 3.2 g/l). One year thereafter serum IgG levels increased significantly (10.1 ± 2.9 g/l) (p

Original languageHungarian
Pages (from-to)1731-1738
Number of pages8
JournalOrvosi Hetilap
Volume147
Issue number36
Publication statusPublished - Sep 10 2006

Fingerprint

Immune System
Neoplasms
Immunoglobulin G
Serum
Drug Therapy
Lymphocyte Subsets
Cytostatic Agents
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Mitogens
Cellular Immunity
Lymphoma
Flow Cytometry
Leukemia
B-Lymphocytes
Quality of Life
Bone and Bones
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gadó, J., Schlick, B., Bárány, O., Németh, J., Müller, J., Csóka, M., ... Kovács, G. (2006). Az immunrendszer állapota gyermekkori malignus daganatok terápiáját követoen. Orvosi Hetilap, 147(36), 1731-1738.

Az immunrendszer állapota gyermekkori malignus daganatok terápiáját követoen. / Gadó, Judit; Schlick, Barbara; Bárány, Olga; Németh, Júlia; Müller, J.; Csóka, Monika; Constantin, T.; Vonnák, Eszter; Böcskei, Renáta; Hauser, P.; Kovács, Gábor.

In: Orvosi Hetilap, Vol. 147, No. 36, 10.09.2006, p. 1731-1738.

Research output: Contribution to journalArticle

Gadó, J, Schlick, B, Bárány, O, Németh, J, Müller, J, Csóka, M, Constantin, T, Vonnák, E, Böcskei, R, Hauser, P & Kovács, G 2006, 'Az immunrendszer állapota gyermekkori malignus daganatok terápiáját követoen', Orvosi Hetilap, vol. 147, no. 36, pp. 1731-1738.
Gadó J, Schlick B, Bárány O, Németh J, Müller J, Csóka M et al. Az immunrendszer állapota gyermekkori malignus daganatok terápiáját követoen. Orvosi Hetilap. 2006 Sep 10;147(36):1731-1738.
Gadó, Judit ; Schlick, Barbara ; Bárány, Olga ; Németh, Júlia ; Müller, J. ; Csóka, Monika ; Constantin, T. ; Vonnák, Eszter ; Böcskei, Renáta ; Hauser, P. ; Kovács, Gábor. / Az immunrendszer állapota gyermekkori malignus daganatok terápiáját követoen. In: Orvosi Hetilap. 2006 ; Vol. 147, No. 36. pp. 1731-1738.
@article{0baf700a54ce48a2b64b5a8c16d85ce7,
title = "Az immunrendszer {\'a}llapota gyermekkori malignus daganatok ter{\'a}pi{\'a}j{\'a}t k{\"o}vetoen",
abstract = "Introduction: Currently, malignancies in childhood can be cured in 70 percent of the cases. However, the intensive cytostatic therapy may lead to late side effects influencing quality of life. Aim of the study: Analysis of the reconvalescence of the immune functions after completion of therapy for malignancies in children. Patients: 88 long-term survivers (51 boys, 37 girls) were investigated (43 acute lymphoid leukemia, 15 lymphoma, 20 bone tumors, 10 other solid tumors). Mean age at the time of diagnosis was 7.8 years (1 mo-17.7 years). Methods: The following parameters were investigated: serum immunglobulin levels after completion of the chemotherapy and in the next 4 years thereafter, lymphocyte subpopulations in the periferal blood by flow-cytometry and cellular immunity by in vitro tests (natural killer aktivity, antibody-dependent cellular cytotoxicity, mitogen-induced T- and B-cell blastic transformations). Results: Lower serum immunglobulin (IgG) levels could be detected in patients with leukemia after completion of the chemotherapy (8.8 ± 3.2 g/l). One year thereafter serum IgG levels increased significantly (10.1 ± 2.9 g/l) (p",
keywords = "Cellular immunity, Chemotherapy, Humoral immunity, Late effects, Malignant diseases",
author = "Judit Gad{\'o} and Barbara Schlick and Olga B{\'a}r{\'a}ny and J{\'u}lia N{\'e}meth and J. M{\"u}ller and Monika Cs{\'o}ka and T. Constantin and Eszter Vonn{\'a}k and Ren{\'a}ta B{\"o}cskei and P. Hauser and G{\'a}bor Kov{\'a}cs",
year = "2006",
month = "9",
day = "10",
language = "Hungarian",
volume = "147",
pages = "1731--1738",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "36",

}

TY - JOUR

T1 - Az immunrendszer állapota gyermekkori malignus daganatok terápiáját követoen

AU - Gadó, Judit

AU - Schlick, Barbara

AU - Bárány, Olga

AU - Németh, Júlia

AU - Müller, J.

AU - Csóka, Monika

AU - Constantin, T.

AU - Vonnák, Eszter

AU - Böcskei, Renáta

AU - Hauser, P.

AU - Kovács, Gábor

PY - 2006/9/10

Y1 - 2006/9/10

N2 - Introduction: Currently, malignancies in childhood can be cured in 70 percent of the cases. However, the intensive cytostatic therapy may lead to late side effects influencing quality of life. Aim of the study: Analysis of the reconvalescence of the immune functions after completion of therapy for malignancies in children. Patients: 88 long-term survivers (51 boys, 37 girls) were investigated (43 acute lymphoid leukemia, 15 lymphoma, 20 bone tumors, 10 other solid tumors). Mean age at the time of diagnosis was 7.8 years (1 mo-17.7 years). Methods: The following parameters were investigated: serum immunglobulin levels after completion of the chemotherapy and in the next 4 years thereafter, lymphocyte subpopulations in the periferal blood by flow-cytometry and cellular immunity by in vitro tests (natural killer aktivity, antibody-dependent cellular cytotoxicity, mitogen-induced T- and B-cell blastic transformations). Results: Lower serum immunglobulin (IgG) levels could be detected in patients with leukemia after completion of the chemotherapy (8.8 ± 3.2 g/l). One year thereafter serum IgG levels increased significantly (10.1 ± 2.9 g/l) (p

AB - Introduction: Currently, malignancies in childhood can be cured in 70 percent of the cases. However, the intensive cytostatic therapy may lead to late side effects influencing quality of life. Aim of the study: Analysis of the reconvalescence of the immune functions after completion of therapy for malignancies in children. Patients: 88 long-term survivers (51 boys, 37 girls) were investigated (43 acute lymphoid leukemia, 15 lymphoma, 20 bone tumors, 10 other solid tumors). Mean age at the time of diagnosis was 7.8 years (1 mo-17.7 years). Methods: The following parameters were investigated: serum immunglobulin levels after completion of the chemotherapy and in the next 4 years thereafter, lymphocyte subpopulations in the periferal blood by flow-cytometry and cellular immunity by in vitro tests (natural killer aktivity, antibody-dependent cellular cytotoxicity, mitogen-induced T- and B-cell blastic transformations). Results: Lower serum immunglobulin (IgG) levels could be detected in patients with leukemia after completion of the chemotherapy (8.8 ± 3.2 g/l). One year thereafter serum IgG levels increased significantly (10.1 ± 2.9 g/l) (p

KW - Cellular immunity

KW - Chemotherapy

KW - Humoral immunity

KW - Late effects

KW - Malignant diseases

UR - http://www.scopus.com/inward/record.url?scp=34748877682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748877682&partnerID=8YFLogxK

M3 - Article

C2 - 17087017

AN - SCOPUS:34748877682

VL - 147

SP - 1731

EP - 1738

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 36

ER -